Regeneron says Covid-19 drug could be less effective against Omicron variant

Regeneron Pharmaceuticals Inc said on Tuesday prior analyses suggested its Covid-19 antibody drug could have reduced activity against the Omicron coronavirus variant. [Reuters]

Subscribe to our Newsletters

Enter your information below to receive our weekly newsletters with the latest insights, opinion pieces and current events straight to your inbox.

SIGN UP NOW

Kathimerini may send occasional special offers and promotions.

By signing up you are agreeing to our Terms of Service and Privacy Policy.